4-氯-2-甲基-6-硝基苯胺 | 62790-50-5

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-2-甲基-6-硝基苯胺
• 英文名称: 4-chloro-2-methyl-6-nitroaniline
• CAS: 62790-50-5
• 化学式: C₇H₇ClN₂O₂
• mdl: MFCD01320687
• 分子量: 186.598
• InChiKey: QDSCDFKGUAONPC-UHFFFAOYSA-N

物化性质

• 熔点：
  126-132 °C
• 沸点：
  328.7±37.0 °C(Predicted)
• 密度：
  1.4800 (rough estimate)
• 稳定性/保质期：

  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2921430090
• 危险品运输编号：
  2811
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	4-Chloro-2-Methyl-6-Nitroaniline 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	62790-50-5

Section 1 - Chemical Product MSDS Name:4-Chloro-2-Methyl-6-Nitroaniline 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
62790-50-5	4-Chloro-2-Methyl-6-Nitroaniline	97	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause cardiac disturbances. May cause methemoglobinemia, cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood), convulsions, and death. The toxicological properties of this substance have not been fully investigated. May cause central nervous system depression.
Inhalation:
Causes respiratory tract irritation. May cause methemoglobinemia, cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood), convulsions, tachycardia, dyspnea (labored breathing), and death. The toxicological properties of this substance have not been fully investigated. May cause cardiac abnormalities. Can produce delayed pulmonary edema. Inhalation at high concentrations may cause CNS depression and asphixiation.
Chronic:
May cause methemoglobinemia, which is characterized by chocolate-brown colored blood, headache, weakness, dizziness, breath shortness, cyanosis (bluish skin due to deficient oxygenation of blood), rapid heart rate, unconsciousness and possible death. Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively. For methemoglobinemia, administer oxygen alone or with Methylene Blue depending on the methemoglobin concentration in the blood.
Antidote: Methylene blue, alone or in combination with oxygen is indicated as a treatment in nitrite induced methemoglobinemia.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Containers may explode in the heat of a fire. Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Substance is noncombustible; use agent most appropriate to extinguish surrounding fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 62790-50-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Needles
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 121-123 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7ClN2O2
Molecular Weight: 186.5142

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 62790-50-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chloro-2-Methyl-6-Nitroaniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 25 Avoid contact with eyes.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 62790-50-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 62790-50-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 62790-50-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-2-甲基-6-硝基苯胺 在 氢气 、 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 2.25h， 生成 7-氯-5-甲基喹喔啉
  参考文献：
  名称：

  8-甲基喹喔啉在混合酸中的硝化

  摘要：

  8-甲基喹喔啉在 40-50 °C 下通过简单的混合酸硝化方案在 C-5 处被有效地硝化。讨论了 C-6 卤素官能化和混合酸条件的修改对相对转化率和工艺安全性的影响。6-卤代-8-甲基喹喔啉的竞争副反应包括在 C-6 的水解和在 C-7 或 C-5 的卤化。

  DOI：

  10.1021/op0340255
• 作为产物：
  描述：

  甲苯-4-磺酸-(4-氯-2-甲基-苯胺) 在 硫酸 、 硝酸 作用下， 生成 4-氯-2-甲基-6-硝基苯胺
  参考文献：
  名称：

  Schuloff; Pollak; Riess, Chemische Berichte, 1929, vol. 62, p. 1855

  摘要：

  DOI：

文献信息

• Novel cinnamic amides
  申请人：Wellner Eric

  公开号：US20050192289A1

  公开（公告）日：2005-09-01

  E-cinnamic amides of piperazine derivatives according to formula (I) wherein X is chloro or fluoro and R 1 is an aromatic or heteroaromatic group, their pharmaceutically acceptable salts or solvates. The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.

  根据公式（I），X为氯或氟，R1为芳香或杂芳基的哌嗪衍生物的E-肉桂酰胺，其药学上可接受的盐或溶剂。该发明还涉及含有公式（I）化合物的药物组合物，以及制备公式（I）化合物的方法，以及通过向哺乳动物施用具有公式（I）的化合物来治疗患有炎症、自身免疫、增殖性或过度增殖性疾病的方法。
• [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
  申请人：UNIV SAARLAND

  公开号：WO2010043711A1

  公开（公告）日：2010-04-22

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  该发明提供特定的小分子化合物，这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用，提供这些化合物的制备方法，包含这些化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
  申请人：Soll Mark David

  公开号：US20140080862A1

  公开（公告）日：2014-03-20

  The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): wherein R 3 , R 4 , R 5 , R 6 , R 7 , P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.

  本发明涉及新颖的式(I)的芳基咪唑-2-基-氰基乙基氨基衍生物：其中R3、R4、R5、R6、R7、P、Q、V、W、X、Y、Z和a如描述中所定义，以及其组合物、制备方法以及它们作为杀虫剂的用途。
• X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease
  作者：Xiang-Li Ning、Yu-Zhi Li、Cui Huo、Ji Deng、Cheng Gao、Kai-Rong Zhu、Miao Wang、Yu-Xiang Wu、Jun-Lin Yu、Ya-Li Ren、Zong-Yuan Luo、Gen Li、Yang Chen、Si-Yao Wang、Cheng Peng、Ling-Ling Yang、Zhou-Yu Wang、Yong Wu、Shan Qian、Guo-Bo Li

  DOI：10.1021/acs.jmedchem.1c00303

  日期：2021.6.24

  nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to 23, which manifested

  人吲哚胺 2,3-双加氧酶 1 (hIDO1) 和色氨酸 2,3-双加氧酶 (hTDO) 与帕金森病 (PD) 的发病机制密切相关；然而，仍然缺乏开发 hIDO1 和 hTDO 双重抑制剂来评估其对抗 PD 的潜在功效。在这里，我们报告的生化、生物物理和计算分析表明，1 H -indmaze-4-amines 通过与血红素亚铁和三价铁态直接协调的机制抑制 hIDO1 和 hTDO。晶体结构指导优化得到23 ，其对hIDO1和hTDO的IC 50值分别为0.64和0.04 μM，并且在小鼠中具有良好的药代动力学特性和脑渗透性。 23显示出对 1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导的小鼠运动协调缺陷的功效，与抗 PD 药物美多芭 (Madopar) 相当。进一步的研究表明，与Madopar不同， 23可能具有特定的抗PD机制，包括降低IDO1表达、减轻多巴胺能神经变性、减少小鼠大脑中